JAK1 and ovarian carcinoma: An in vitro study with one endometrial cancer and two ovarian cancer cell lines harboring JAK1 frameshift mutations demonstrated that JAK1 mutations impede STAT1 posphorylation and upregulation of antigen presenting machinery components LMP2 and TAP1 [10].